176 related articles for article (PubMed ID: 36778367)
1. Unstable EBV latency drives inflammation in multiple sclerosis patient derived spontaneous B cells.
Soldan S; Su C; Monaco MC; Brown N; Clauze A; Andrada F; Feder A; Planet P; Kossenkov A; Schäffer D; Ohayon J; Auslander N; Jacobson S; Lieberman P
Res Sq; 2023 Feb; ():. PubMed ID: 36778367
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease.
Soldan SS; Su C; Monaco MC; Yoon L; Kannan T; Zankharia U; Patel RJ; Dheekollu J; Vladimirova O; Dowling JW; Thebault S; Brown N; Clauze A; Andrada F; Feder A; Planet PJ; Kossenkov A; Schäffer DE; Ohayon J; Auslander N; Jacobson S; Lieberman PM
Nat Microbiol; 2024 May; ():. PubMed ID: 38806670
[TBL] [Abstract][Full Text] [Related]
3. EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls.
Monaco MCG; Soldan SS; Su C; Clauze A; Cooper JF; Patel RJ; Lu F; Hughes RJ; Messick TE; Andrada FC; Ohayon J; Lieberman PM; Jacobson S
Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37562974
[TBL] [Abstract][Full Text] [Related]
4. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation.
Price AM; Luftig MA
Adv Virus Res; 2014; 88():279-313. PubMed ID: 24373315
[TBL] [Abstract][Full Text] [Related]
6. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
8. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
9. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
Rowe M; Lear AL; Croom-Carter D; Davies AH; Rickinson AB
J Virol; 1992 Jan; 66(1):122-31. PubMed ID: 1309242
[TBL] [Abstract][Full Text] [Related]
10. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
Serafini B; Rosicarelli B; Veroni C; Mazzola GA; Aloisi F
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578295
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis.
Veroni C; Serafini B; Rosicarelli B; Fagnani C; Aloisi F
J Neuroinflammation; 2018 Jan; 15(1):18. PubMed ID: 29338732
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
Drosu NC; Edelman ER; Housman DE
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
[TBL] [Abstract][Full Text] [Related]
14. Nascent Transcriptomics Reveal Cellular Prolytic Factors Upregulated Upstream of the Latent-to-Lytic Switch Protein of Epstein-Barr Virus.
Frey TR; Brathwaite J; Li X; Burgula S; Akinyemi IA; Agarwal S; Burton EM; Ljungman M; McIntosh MT; Bhaduri-McIntosh S
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941784
[TBL] [Abstract][Full Text] [Related]
15. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
16. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
17. Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis.
Meier UC; Cipian RC; Karimi A; Ramasamy R; Middeldorp JM
Front Immunol; 2021; 12():757302. PubMed ID: 34790199
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation.
Serafini B; Severa M; Columba-Cabezas S; Rosicarelli B; Veroni C; Chiappetta G; Magliozzi R; Reynolds R; Coccia EM; Aloisi F
J Neuropathol Exp Neurol; 2010 Jul; 69(7):677-93. PubMed ID: 20535037
[TBL] [Abstract][Full Text] [Related]
19. Cellular factors associated with latency and spontaneous Epstein-Barr virus reactivation in B-lymphoblastoid cell lines.
Davies ML; Xu S; Lyons-Weiler J; Rosendorff A; Webber SA; Wasil LR; Metes D; Rowe DT
Virology; 2010 Apr; 400(1):53-67. PubMed ID: 20153012
[TBL] [Abstract][Full Text] [Related]
20. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Front Immunol; 2023; 14():878953. PubMed ID: 37033971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
